Medicare Part B may help with the costs of Keytruda. Outpatient facilities usually administer the drug intravenously, and Part B covers outpatient services. The generic name for Keytruda is ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with ...

TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.

AstraZeneca PLC (NASDAQ: AZN)'s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Novartis has entered into an exclusive licence agreement with Legend Biotech for global rights to a selection of CAR-T cell therapies targeting DLL3, with the deal potentially worth over $1bn. Under ...

Isas were launched by Gordon Brown in 1999. Cash versions are the more popular than stocks and shares ones, with some £421billion held in cash Isas out of the total £726billion held in Isas in ...